GLP-1 Drugs and the Gut: What the Trials Reported

This article describes published findings about a class of prescription medicines. It is not advice about your prescription. Nothing here is a reason to start, stop, change, or delay any medication, and every question about your own regimen belongs with the clinician who prescribes it.

With that said, GLP-1 receptor agonists are unusual among widely used drugs in that their effects on the digestive tract are not a side story. They are part of the mechanism.

The hormone the drugs imitate

Glucagon-like peptide-1 is a hormone released from the gut within minutes of eating. A 2007 review in Gastroenterology summarizing incretin biology describes GLP-1 as exerting glucoregulatory actions through slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion, and notes that GLP-1 also promotes satiety, with sustained GLP-1 receptor activation associated with weight loss in both preclinical and clinical studies.¹

The same review explains why long-acting synthetic versions exist at all: native GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4, which led to the development of degradation-resistant GLP-1 receptor agonists.¹

So slowed gastric emptying and altered appetite are not accidental consequences of these drugs. They are among the actions of the hormone being mimicked.

What the weight loss trials recorded

STEP 1 enrolled 1,961 adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related coexisting condition, who did not have diabetes. Participants were randomized 2 to 1 to 68 weeks of once-weekly subcutaneous semaglutide at 2.4 mg or placebo, both alongside lifestyle intervention.²

Mean body weight change from baseline to week 68 was minus 14.9 percent with semaglutide against minus 2.4 percent with placebo. On the digestive side, the trial reported that nausea and diarrhea were the most common adverse events with semaglutide, that they were typically transient and mild to moderate in severity, and that they subsided with time. More participants in the semaglutide group than the placebo group discontinued because of gastrointestinal events: 59 participants, or 4.5 percent, against 5 participants, or 0.8 percent.²

Two figures from one trial are worth holding together. Digestive symptoms were the most common adverse events, and roughly one in twenty participants stopped the drug because of them, against roughly one in 125 on placebo.

Gastric emptying: less settled than it sounds

“These drugs slow your stomach down” is the usual summary. The measured picture is more specific.

A randomized, double-blind, placebo-controlled crossover trial in 30 subjects with obesity gave once-weekly subcutaneous semaglutide escalated to 1.0 mg, or placebo, for 12 weeks per period, and assessed gastric emptying by paracetamol absorption. First-hour gastric emptying after a standardized meal was delayed with semaglutide, with an estimated ratio of 0.73. Overall gastric emptying across five hours was not statistically different between the two conditions.³

A separate double-blind, parallel-group trial in 72 adults with obesity used the higher 2.4 mg weekly dose over 20 weeks and assessed gastric emptying by the same paracetamol method. Paracetamol area under the curve over five hours was 8 percent higher with semaglutide than placebo, a difference that was not significant once corrected for week 20 body weight. No effect was seen on the first-hour measure, on maximum paracetamol concentration, or on time to that maximum. The authors concluded there was no evidence of delayed gastric emptying at week 20 by this method.⁴

The same trial found large effects on intake and appetite: ad libitum energy intake was 35 percent lower with semaglutide than placebo, hunger and prospective food consumption were reduced, fullness and satiety increased, and body weight fell 9.9 percent against 0.4 percent.⁴

Read together: an early-phase delay in gastric emptying was measured at one dose and timepoint and not at another, and the appetite effects were substantial in both. Anyone assuming that every digestive symptom on these drugs is explained by a slowed stomach is assuming more than these two trials show. Both trials were sponsored by the manufacturer, and both disclose that several authors were company employees.³⁴

The less common events

Beyond nausea and diarrhea, a 2023 research letter in JAMA examined records for serious gastrointestinal events using the PharMetrics Plus claims database covering 2006 to 2020. The cohort comprised 4,144 liraglutide users, 613 semaglutide users, and 654 users of bupropion-naltrexone, a weight loss agent unrelated to GLP-1 agonists, which served as the comparator.⁵

Incidence rates per 1,000 person-years were reported as follows. Pancreatitis: 4.6 with semaglutide, 7.9 with liraglutide, 1.0 with bupropion-naltrexone. Bowel obstruction: 0 with semaglutide, 8.1 with liraglutide, 1.7 with bupropion-naltrexone. Gastroparesis: 9.1 with semaglutide, 7.3 with liraglutide, 3.1 with bupropion-naltrexone. Biliary disease: 11.7 with semaglutide, 18.6 with liraglutide, 12.6 with bupropion-naltrexone.⁵

Compared with bupropion-naltrexone, adjusted hazard ratios for GLP-1 agonist use were 9.09 for pancreatitis with a 95 percent confidence interval of 1.25 to 66.00, 4.22 for bowel obstruction with an interval of 1.02 to 17.40, and 3.67 for gastroparesis with an interval of 1.15 to 11.90. The hazard ratio for biliary disease was 1.50 with an interval of 0.89 to 2.53, which is not statistically significant.⁵

Those confidence intervals deserve as much attention as the point estimates. An interval running from 1.25 to 66.00 is compatible with a small increase and with an enormous one, which is what happens when the absolute number of events is low. The authors also state a limitation directly: although all GLP-1 agonist users had a record for obesity without diabetes, whether the drugs were all used for weight loss is uncertain.⁵

This is observational claims data, not a randomized comparison, so it can show association and cannot establish cause.

What this adds up to

The digestive effects of GLP-1 receptor agonists are expected rather than surprising, because slowed gastric emptying and appetite suppression are among the documented actions of the hormone these drugs are designed to mimic.¹

In the largest randomized evidence, nausea and diarrhea were the most common adverse events, generally transient and mild to moderate, and a small but real fraction of participants discontinued because of them.² In observational claims data, rarer serious events including pancreatitis, bowel obstruction, and gastroparesis were recorded at higher rates than with a non-GLP-1 comparator, with wide confidence intervals and the usual limits of an observational design.⁵

None of that is a reason to act on your own. Severe or persistent vomiting, abdominal pain that does not settle, or an inability to keep fluids down are reasons to contact a clinician promptly rather than to search for a supplement. Any decision about starting, adjusting, pausing, or stopping a GLP-1 medicine is a decision for you and your prescriber, made with your full history in front of them.